Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood
Xiaoqian Xu, Jun Yang, Yu Cai, Li Su, Jiahua Niu, Kun Zhou, Ying Jiang, Xiaowei Xu, Chang Shen, Chongmei Huang, Huiying Qiu, Daolin Wei, Mei Kang, Yin Tong, Zheng Wei, Peng Liu, Liping Wan, Xianmin Song
Abstract
For successful transplantation using a haploidentical donor, it requires effective depletion of T cells to reduce the risk of graft-versus-host disease (GvHD) and prevent serious GvHD. Contemporary practice of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) frequently adopts in vivo T-cell depletion strategies: a monoclonal antibody against T cells using antihuman thymocyte immunoglobulin (ATG)
Topics & Concepts
Anti-thymocyte globulinMedicineCyclophosphamideGraft-versus-host diseaseGlobulinThymocyteTransplantationChemotherapySurgeryImmunologyT cellImmune systemHematopoietic Stem Cell TransplantationT-cell and B-cell ImmunologyImmunotherapy and Immune Responses